5) No significant difference in the incidence of CNS-related ARs in pediatric patients treated with 0.2 mg/kg/week of Jintrolong® (0.009 μmol PEG-GH/kg/week) and Jintropin (GH) further supports the long-term use of Jintrolong® in clinical. This evidence concerns the gene GH1 and Axenfeld-Rieger syndrome.